Latisse history


Bimatoprost 0.03% ophthalmic solution was originally used as an eyedrop to treat glaucoma, a condition in which the pressure within the globe of the eye is above the upper limits of normal. It was applied daily for the rest of the patients life, as it was a treatment but not a cure, and millions of patient years have been recorded and studied.
A well documented side effect from using this treatment was eyelash growth. Latisse is a prostaglandin analogue and it has since been found that these can act to stimulate the hair growth cycle, resulting in hair that is longer, thicker and darker. This resulted in many patients growing long thick eyelashes which were very noticeable. Some people did not necessarily find this a bad side effect and others desired the results that the treatment provided.
Mylash was founded in 2007 and used this original eyedrop. It is applied topically to the skin at the base of the eyelashes using a precision applicator.
In 2008, the American FDA gave approval for the cosmetic use of bimatoprost 0.03% under the name Latisse. The ingredients are the same as the original, as are the concentrations of all the ingredients and the bottle that it is supplied in. The only difference is the packaging and that it is supplied with applicators.
To gain FDA approval the safety profile of the treatment had to be studied. Luckily there was years of data on the use of the liquid directly on the eye and they found that there was significantly less side effects when applied to the skin, possibly due to the lower dose used as it is a smaller area and because the skin is less sensitive. The results were also documented and it was found that the average trial participant grew eyelashes that were 25% longer, 106% thicker and 18% darker.

Latisse UK

Comments

Popular posts from this blog

Stylist reviews Mylash

Time to anti-age your eyelashes

Beauty insider